Ironwood Pharmaceuticals (IRWD) Stock Forecast, Price & News

Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions

Is Ironwood Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ironwood Pharmaceuticals stock.
View analyst ratings for Ironwood Pharmaceuticals or view top-rated stocks.

When is Ironwood Pharmaceuticals' next earnings date?

Ironwood Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Ironwood Pharmaceuticals.

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its quarterly earnings results on Thursday, May, 5th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by $0.10. The biotechnology company had revenue of $97.53 million for the quarter, compared to the consensus estimate of $96.62 million. Ironwood Pharmaceuticals had a net margin of 124.83% and a trailing twelve-month return on equity of 33.93%. The company's revenue was up 9.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.24 EPS.
View Ironwood Pharmaceuticals' earnings history.

What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?

Ironwood Pharmaceuticals issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $420.00 million-$430.00 million, compared to the consensus revenue estimate of $429.48 million.

What price target have analysts set for IRWD?

3 brokerages have issued 1 year target prices for Ironwood Pharmaceuticals' stock. Their forecasts range from $14.00 to $16.00. On average, they anticipate Ironwood Pharmaceuticals' stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 28.8% from the stock's current price.
View analysts' price targets for Ironwood Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Ironwood Pharmaceuticals' key executives?

Ironwood Pharmaceuticals' management team includes the following people:

• Ms. Julie H. McHugh, Exec. Chairman (Age 58, Pay $155k) (LinkedIn Profile)
• Mr. Thomas A. McCourt, CEO & Director (Age 65, Pay $1.57M) (LinkedIn Profile)
• Mr. Sravan Kumar Emany, Sr. VP, Principal Financial Officer & CFO (Age 44, Pay $228.89k)
• Mr. Jason Rickard, Sr. VP & COO (Age 51, Pay $959.33k) (LinkedIn Profile)
• Mr. John Minardo, Sr. VP, Chief Legal Officer & Sec. (Age 46, Pay $553.29k)
• Dr. Michael Shetzline M.D., Ph.D., Chief Medical Officer, Sr. VP and Head of Research & Drug Devel. (Age 63, Pay $907.94k) (LinkedIn Profile)
• Mr. Ronald Silver, Corp. Controller & Principal Accounting Officer (Age 40) (LinkedIn Profile)
• Mr. Marcel Moulaison, VP of Technical Operations
• Mr. Mike Nanfito, VP of Sales & Sales Excellence
• Dr. Christopher I. Wright, Chief Devel. Officer & Sr. VP of Global Devel.

What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO?

7 employees have rated Ironwood Pharmaceuticals CEO Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among Ironwood Pharmaceuticals' employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Ironwood Pharmaceuticals' key competitors?

Some companies that are related to Ironwood Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), United Therapeutics (UTHR), Repligen (RGEN), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of IRWD's competitors.

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.13%), Vanguard Group Inc. (8.39%), State Street Corp (5.21%), LSV Asset Management (4.65%), Renaissance Technologies LLC (1.96%) and Dimensional Fund Advisors LP (1.93%). Company insiders that own Ironwood Pharmaceuticals stock include Alexander J Denner, Jason Rickard, Julie Mchugh, Kelly Macdonald, Mark G Currie, Michael Shetzline, Ronald Silver, Thomas A Mccourt and Timothy M O'reilly.
View institutional ownership trends for Ironwood Pharmaceuticals.

Which institutional investors are selling Ironwood Pharmaceuticals stock?

IRWD stock was sold by a variety of institutional investors in the last quarter, including Foundry Partners LLC, Prudential Financial Inc., Federated Hermes Inc., AlphaCrest Capital Management LLC, State Board of Administration of Florida Retirement System, Great Lakes Advisors LLC, Skandinaviska Enskilda Banken AB publ , and Vanguard Group Inc.. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Jason Rickard, Julie Mchugh, Mark G Currie, Michael Shetzline, Ronald Silver, and Thomas A Mccourt.
View insider buying and selling activity for Ironwood Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Ironwood Pharmaceuticals stock?

IRWD stock was acquired by a variety of institutional investors in the last quarter, including Royce & Associates LP, Renaissance Technologies LLC, State Street Corp, SG Americas Securities LLC, State of New Jersey Common Pension Fund D, First Trust Advisors LP, BlackRock Inc., and Healthcare of Ontario Pension Plan Trust Fund. Company insiders that have bought Ironwood Pharmaceuticals stock in the last two years include Alexander J Denner, and Timothy M O'reilly.
View insider buying and selling activity for Ironwood Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ironwood Pharmaceuticals' stock price today?

One share of IRWD stock can currently be purchased for approximately $11.65.

How much money does Ironwood Pharmaceuticals make?

Ironwood Pharmaceuticals has a market capitalization of $1.79 billion and generates $413.75 million in revenue each year. The biotechnology company earns $528.45 million in net income (profit) each year or $3.19 on an earnings per share basis.

How many employees does Ironwood Pharmaceuticals have?

Ironwood Pharmaceuticals employs 219 workers across the globe.

What is Ironwood Pharmaceuticals' official website?

The official website for Ironwood Pharmaceuticals is www.ironwoodpharma.com.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The biotechnology company can be reached via phone at (617) 621-7722, via email at [email protected], or via fax at 617-494-0480.